Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nuveen California Select Tax-Free Income Portfolio is a closed-ended fixed income mutual fund launched by Nuveen Investments Inc. The fund is co-managed by Nuveen Fund Advisors LLC and Nuveen Asset Management, LLC. It invests in the fixed income markets of California. The fund invests in the securities of companies that operate across diversified sectors. It primarily invests in municipal bonds. The fund employs fundamental analysis to create its portfolio. It benchmarks the performance of its portfolio against Barclays Capital California Municipal Bond Index and S&P California Municipal Bond Index. Nuveen California Select Tax-Free Income Portfolio was formed on June 19, 1992 and is domiciled in the United States.

Nuveen California Select Tax-Free Income Portfolio

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CHICAGO--(BUSINESS WIRE)--SHAREHOLDERS OF THE NUVEEN SELECT TAX-FREE INCOME PORTFOLIO (NYSE: NXP), NUVEEN CALIFORNIA SELECT TAX-FREE INCOME PORTFOLIO (NYSE: NXC), AND NUVEEN NEW YORK SELECT TAX-FREE INCOME PORTFOLIO (NYSE: NXN) HAVE APPROVED THE FUNDS' REORGANIZATION. THE REORGANIZATION WILL COMBINE NXC AND NXN INTO NXP. SUBJECT TO THE SATISFACTION OF CERTAIN CUSTOMARY CLOSING CONDITIONS, THE TRANSACTIONS ARE EXPECTED TO BECOME EFFECTIVE BEFORE THE MARKET OPENS ON JANUARY 12, 2026. THE MONTHLY.

NUVEEN SELECT TAX-FREE INCOME PORTFOLIOS ANNOUNCE SHAREHOLDER APPROVAL OF REORGANIZATION

- FORMER CHIMERIX (CMRX, ACQUIRED BY JAZZ FOR $935 MILLION) SENIOR COMMERCIAL LEADER MICHAEL GRABOW LED GO-TO-MARKET STRATEGY AND LAUNCH FOR RARE DISEASE THERAPEUTIC MODEYSO -

IMMIX BIOPHARMA APPOINTS CHIEF COMMERCIAL OFFICER TO DRIVE NXC-201 LAUNCH

- ORAL PRESENTATION SUNDAY, DECEMBER 7, AT ASH 2025 - LOS ANGELES, NOV. 03, 2025 (GLOBE NEWSWIRE) -- IMMIX BIOPHARMA, INC. (IMMIXBIO, COMPANY, WE OR US OR IMMX), THE GLOBAL LEADER IN RELAPSED/REFRACTORY AL AMYLOIDOSIS, TODAY ANNOUNCED THAT PHASE 1/2 INTERIM RESULTS FROM ITS U.S. NXC-201 NEXICART-2 TRIAL IN RELAPSED/REFRACTORY AL AMYLOIDOSIS HAS BEEN SELECTED FOR ORAL PRESENTATION AT THE UPCOMING AMERICAN SOCIETY OF HEMATOLOGY 2025 ANNUAL MEETING (ASH 2025) BEING HELD IN ORLANDO, FLORIDA, DECEMBER 69, 2025. ASH 2025 PRESENTATION DETAILS  NXC-201 TITLE FIRST 20-PATIENT SAFETY AND EFFICACY DATA FROM NEXICART-2, THE FIRST U.S. TRIAL OF CAR-T IN R/R LIGHT CHAIN (AL) AMYLOIDOSIS, NXC-201 PRESENTATION DATE/TIME (EASTERN TIME) PRESENTATION DATE: DECEMBER 7, 2025 PRESENTATION TIME: 5:45 PM - 6:00 PM ET PRESENTATION ABSTRACT NUMBER: ABS25-14730 SESSION NAME: 652.

Nuveen California Select Tax-Free Income Portfolio

NXC

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Nuveen California Select Tax-Free Income Portfolio

NXC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

NXC